InMed Pharmaceuticals

In an #Alzheimer's disease preclinical in vivo study, InMed's INM-901 showed it reduced markers of #neuroinflammation. -Improved cytokine profile. Cytokine networks, when deregulated, may contribute to tissue #inflammation -Reduction in neurodegeneration biomarker - reduces neurofilament light chain (NfL). NfL levels are used to assess cellular damage in #neurodegenerative disease More about INM-901 here: https://ow.ly/JCPy50Vnzct $INM

Alzheimer's disease experts discuss innate immune function and its correlation with disease risk. "Genetics are really pointing us in certain directions and, in some cases, it appears that it's a decrease in the innate immune function that's associated with increased disease risk. These are things we're going to have to really work through on a very detailed basis." ~Dr. David Morgan, Michigan State University Webinar includes discussion on the role of neuroinflammation, new biological pathways and what's next in Alzheimer's disease research and treatments. Webinar here: https://ow.ly/G5NJ50VhzOP $INM #Alzheimers #research #immunefunction

What are the different types of age-related macular degeneration #AMD? There two primary types of AMD – dry AMD and wet AMD. Dry AMD is the most common form of AMD, accounting for 80% of AMD cases according to the American Academy of Ophthalmology. Dry AMD typically takes several years to progress and happens in three stages – early, intermediate and late stage. The late or advanced stage of dry AMD is also referred to as geographic atrophy (GA). In the advanced stage of dry AMD, the retina has atrophied and the macula has wasted away, leading to the loss of a person’s central vision. Wet AMD, also referred to as exudative AMD, progresses quickly and occurs when abnormal blood vessels grow at the back of the eye causing macular damage. Learn more about AMD: https://ow.ly/jtu150VhH5e $INM

In this webinar, Alzheimer's leaders talk about how recent R&D progress will make a meaningful impact on improving patient qualify of life. "I don't think we'll cure Alzheimer's in our lifetime. I think we will make it a chronic disease, much like we did with diabetes. But the end point will be that people will live good qualities of life. They will retain their sense of self, they will retain their agency, and autonomy, and their voice, and their ability to make their own decisions. And that is very important. Their quality of life will be retained." ~Dr. Marwan Sabbagh, Barrow Neurological Institute Experts talk about the role of neuroinflammation, new biological pathways and what's on the horizon for Alzheimer's disease research and treatments: https://ow.ly/smo950VgGOv $INM #Alzheimers #research #neuroinflammation

In the video, CEO Eric A. Adams talks about the different pathological factors that lead to the development and progression of #Alzheimer’s disease and how preclinical studies of INM-901 indicate how this small molecule drug candidate may address multiple mechanisms related to this disease. Watch here: https://ow.ly/4w7r50VeYVl $INM #Alzheimers #pathology

What is neuritogenesis and how does it affect Alzheimer's disease progression? Neuritogenesis is the extension of neurites, which are the branchlike structures extending from a neuron and are essential for cell-to-cell communication in the brain. The neuritogenesis process slows down in adults, and to a greater degree in a brain affected by Alzheimer’s disease. The regrowth of neurites or extension of neurites presents an opportunity to reverse neuronal damage caused by Alzheimer’s disease. More here: https://ow.ly/ePkc50V9FFQ $INM #Alzheimers #pathology #neuritogenesis

Population diversity in #Alzheimers clinical trials helps to develop a more personalized treatment plan for patients. Data from a diverse group also gives researchers a deeper understanding of how biomarkers, genetic makeup, geographic impact and other measures impact Alzheimer's disease. More on Alzheimer's clinical trials: https://ow.ly/QOyi50V794y $INM

Researchers at the Allen Institute have uncovered some of the early changes in the brain that occur before Alzheimer's disease symptoms appear. This includes the death of cells called somatostatin (SST) inhibitory neurons. More here: https://ow.ly/7Qgm50V73Ur $INM #Alzheimers #research

In this webinar, Alzheimer's disease experts say advances in diagnostics have been instrumental in understanding Alzheimer's pathology and early disease development. "This disease starts in the brain, with pathology 10 to 20 years before symptoms, so we’ve had a pretty late view of this disease until recently. With some fantastic technology and improvement in the diagnostics, we don’t have to be so late anymore." ~Dr. Phyllis Ferrell, Executive Director of Alzheimer's Moonshot Watch webinar: https://ow.ly/EXvb50V6e7t $INM #Alzheimers #research

Researchers are finding that brain changes can occur 20+ years before #Alzheimer’s disease development. Abnormal levels of neurofilament light chain protein, a biomarker of #neurodegeneration, are found to start about 22 years before #Alzheimers symptoms develop. More in this Alzheimer's Association® report: https://ow.ly/QYY250V5xOO $INM